Pharmafile Logo
Pharmafocus logo
Advanced Search
brexit

The impact of Brexit on the pharmaceutical industry: some preliminary considerations

August 1, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing brexit

The outcome of the popular vote cast on 23 June 2016 will be remembered as the start of a new …

Feature

Sartorius doubles production capacity in UK with new facility

August 1, 2016
Manufacturing and Production, Sales and Marketing Princess Anne, Sartorius, UK, expansion

Pharmaceutical and laboratory equipment provider Sartorius has expanded operations at its Stonehouse site in Gloucestershire with a new plant, doubling …

News
merck_and_co

European Commission approves Zepatier for chronic hepatitis C infection

August 1, 2016
Research and Development, Sales and Marketing

MSD, known as Merck in the US and Canada, has announced that the European Commission has approved Zepatier (elbasvir/grazoprevir) with …

News

Surprise for Seres as shares sent tumbling by Phase II failure

August 1, 2016
Research and Development, Sales and Marketing FDA, clostrodium difficile, seres therapeutics

Seres Therapeutics has presented interim results from an ongoing Phase II trial which has sent company stock spiralling downward, as …

News
a_scientist_at_work_at_sanofis_immunology_laboratory_in_thailand

EMA accepts MMA for rheumatoid arthritis treatment Sarilumab

August 1, 2016
Research and Development, Sales and Marketing EMA, MAA, Regeneron, Sanofi, sarilumab

Sanofi and Regeneron Pharmaceuticals have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for …

News
GSK image

GSK and Alphabet to create bioelectronics medicines in £540 million partnership

August 1, 2016
Research and Development, Sales and Marketing Alphabet, GSK, Verily, bioelectronic medicine, galvani, google

GlaxoSmithKline and Verily Life Sciences, a division of Google’s parent company Alphabet, have announced a £540 million partnership that will …

News
antiviralresearch

FDA fast tracks Shire’s SHP626 nonalcoholic steatohepatitis drug

July 29, 2016
Research and Development FDA, SHP626, Shire, liver fibrosis, nash, volixibat, volxibat

The Food and Drug Administration (FDA) has granted Fast Track designation to Shire’s SHP626 (volixibat) treatment for patients suffering from …

News
humacao_exterior

Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016

July 29, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo

Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps …

News

China’s Fosun seals $1.3 billion deal for Gland Pharma

July 29, 2016
Medical Communications, Sales and Marketing acquisition, fosun, gland, takeover

Fosun Pharmaceutical has agreed a deal to purchase an 86.1% stake of Gland Pharma, which will see the Chinese firm …

News

Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial

July 29, 2016
Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis

Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …

News
sanofi_hq_reception_close

Earnings drop at Sanofi as it looks for a quick Medivation resolution

July 29, 2016
Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings

Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …

News
roche_close

Roche urges reform of Cancer Drugs Fund as NICE takes control

July 29, 2016
Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE, Roche

Roche has warned that cancer patients in England are facing into an “uncertain future” as the new Cancer Drugs Fund …

News

Ashfield provides clarity on the age old debate: ‘Syndicated’ or ‘Dedicated’ field sales?

July 28, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Ashfield is understandably well placed to offer a balanced viewpoint on field sales teams. With over 20 years of experience, …

News
Press release
blue_jeans

Strong early data on haemophilia gene therapy boosts Biomarin

July 28, 2016
Medical Communications, Research and Development BioMarin, gene therapy, haemophilia a

Biomarin has presented interim results from a Phase I/II study that is being hailed as positive “proof-of-concept” data for their …

News
astrazeneca_building_white

Cholesterol drugs drag AstraZeneca’s profits down in latest financial results

July 28, 2016
Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results

AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …

News
shutterstock_212432119

LMTX fails Phase III trial, monotherapy benefits seen

July 28, 2016
Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure

TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …

News
sanofi_hq__boetie_hall

Sanofi gets FDA approval for type-2 diabetes treatment Adlyxin

July 28, 2016
Research and Development, Sales and Marketing FDA, Lixisenatide, Lyxumia, Sanofi, adlyxin, approval, diabetes, type 2, type-2, zealand

Sanofi has announced that the US Food and Drug Administration (FDA) has approved Adlyxin (lixisenatide), which is a once-daily mealtime …

News
johnnolech

John Lechleiter to step down as Lilly CEO

July 27, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, John Lechleiter

Eli Lilly has announced that CEO John Lechleiter is set to retire, with David Ricks to assume the role as …

News

Shire and BMS secure NICE recommendations for oncology drugs

July 27, 2016
Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …

News
shutterstock_87495637

Orkambi deemed not suitable for NHS use

July 27, 2016
Manufacturing and Production, Research and Development Orkambi, Vertex, Vertex Pharma, cystic fibrosis

The National Institute for Health and Care Excellence (NICE) has issued its recommendation that the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) …

News
The Gateway to Local Adoption Series

Latest content

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026

Study explores speech as marker in rare neurodegenerative disease

April 27, 2026

Ofichem brings all brands under single trading name

April 23, 2026